ÂÜÀòÂÒÂ×

Dr. Tony Tong is a Principal of Decheng Capital and has been with the firm since May 2014. He has an interest in diverse sectors within the China healthcare industry. He currently serves on the boards of AnHeart Therapeutics, CardiMED, Insight Lifetech and LYNK Pharmaceuticals.

Prior to joining Decheng Capital, Dr. Tong was a Vice President at Mingly China Growth Fund (MCGF), focusing on evaluating investment opportunities in the healthcare sector and serving on the boards of Yocaly (acquired by Lepu Medical), Family of Health (partially acquired by Sunshine Insurance), Sonicmed and Baifendian Technology. From 2009 to 2012, Dr. Tong was Senior Investment Associate at Yifang Ventures, a venture capital investment and asset management firm founded by Dr. Eric Xu, the Co-founder of . Dr. Tong received his PhD in Biochemistry and Molecular Biology from Institute of Biophysics of Chinese Academy of Science, a BS degree in Life Science from University of Science and Technology of China and the second BS degree in Economics from Peking University.